Related Experiment Video
Updated: Jun 27, 2026
14:48
Visualizing Lung Cellular Adaptations during Combined Ozone and LPS Induced Murine Acute Lung Injury
Published on: March 21, 2021
Fatal pneumonitis induced by oxaliplatin
Sara Arévalo Lobera1, Naiara Sagastibeltza Mariñelarena, Ibone Elejoste Echeberría
1Department of Medical Oncology, Hospital Donostia, Donostia, Guipúzcoa, Spain. sara.arevalo@osakidetza.net
Summary
Oxaliplatin is approved for colorectal cancer treatment. However, severe, fatal pulmonary toxicity, including interstitial pneumonitis and pulmonary fibrosis, has been rarely observed.
Area of Science:
- Oncology
- Pulmonology
- Clinical Pharmacology
Background:
- Oxaliplatin is a key chemotherapeutic agent for adjuvant treatment of colorectal cancer.
- While generally manageable, oxaliplatin can induce moderate toxicities.
- Rare instances of severe pulmonary toxicity have been documented.
Observation:
- This report details two fatal cases of severe pulmonary toxicity associated with oxaliplatin.
- The observed toxicity manifested as interstitial pneumonitis.
- The condition rapidly progressed to pulmonary fibrosis.
Findings:
- Two patients experienced severe, life-threatening pulmonary complications following oxaliplatin treatment.
- The cases highlight a rare but severe adverse effect profile of oxaliplatin.
- Rapid evolution from interstitial pneumonitis to pulmonary fibrosis was noted.
Implications:
- Clinicians should be vigilant for potential severe pulmonary toxicity in patients receiving oxaliplatin.
- Early recognition and management strategies for oxaliplatin-induced lung injury are crucial.
- Further research may be warranted to understand the mechanisms and risk factors for this rare toxicity.
Related Concept Videos
01:30Pneumonia I: Introduction
Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
01:29Pneumonia I: Introduction
Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...
01:26Pneumothorax-I
A pneumothorax is a condition where air builds up in the space between the lung and the chest wall, causing the lung to collapse. This condition arises when air enters the space between the parietal and visceral pleura, disrupting the negative pressure essential for lung inflation. This can lead to a partial or complete collapse of the lung.
Pneumothorax can be even further classified as spontaneous, traumatic, and tension pneumothorax.
Pneumothorax can be even further classified as spontaneous, traumatic, and tension pneumothorax.
01:29Pneumonia II: Pathophysiology
The pathophysiology of pneumonia involves the following steps:
01:27Pneumothorax-II
Pneumothorax is a medical condition defined by the buildup of air in the pleural space between the lungs and the chest wall. This accumulation of air can lead to partial or complete lung collapse, resulting in a range of clinical manifestations. Understanding the clinical presentation and effective management strategies is crucial for healthcare professionals in providing timely and appropriate care to individuals with pneumothorax.
Clinical Manifestations:
Clinical Manifestations:
01:28Pneumonia IV: Management
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include: